Alfasigma S.p.A. has completed the acquisition of Intercept Pharmaceuticals, Inc. through its subsidiary Interstellar Acquisition Inc. The transaction included the successful purchase of all Intercept shares by Alfasigma at a price of USD 19.00 per share.
Following the completion of the tender offer, Alfasigma acquired the remaining shares through a merger, converting Intercept into its 100% subsidiary. As a result, Intercept shares ceased trading on the NASDAQ Stock Market.
With this acquisition, Alfasigma incorporates Ocaliva into its portfolio, the only second-line treatment approved by the FDA for primary biliary cholangitis (PBC).
The operation will strengthen Alfasigma's pipeline, adding a novel fixed combination that could establish a new paradigm in PBC treatment.
Stefano Golinelli, President of Alfasigma, expressed his enthusiasm for the successful offer and highlighted that this transaction will strengthen Alfasigma's presence in the attractive U.S. market.
The acquisition represents a significant advance in Alfasigma's international growth plans, and productive collaboration with Intercept is expected to offer innovative and effective treatment options for severe liver diseases, as well as to expand the business in the United States.
It is important to note that this press release contains forward-looking statements involving risks and uncertainties.
Alfasigma emphasizes its commitment to improving the health and quality of life of people through high-quality and safe therapeutic solutions.
Intercept, for its part, is a biopharmaceutical company focused on the development and commercialization of treatments for rare and severe liver diseases.
The safety and efficacy of Ocaliva are supported by clinical studies, but warnings are issued about possible side effects, including severe pruritus, HDL-C reduction, and liver complications, especially in patients with cirrhosis.
Patients and healthcare professionals are advised to be alert to possible adverse effects and to follow the monitoring and management recommendations provided in the medication's safety information.
Based on information from: Intercept.
Receive all industry news in our weekly Newsletter Dialéctica Científica.